Association between statin treatment and new-onset diabetes mellitus: a population based case–control study

Statin use and risk of new-onset diabetes: A meta-analysis of observational studies

(2017) M. Casula et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Cohort Profile: The National Health Insurance Service–National Sample Cohort (NHIS-NSC), South Korea

(2016) Juneyoung Lee et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Statin use and the risk of developing diabetes: a network meta-analysis

(2016) Divyesh Thakker et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes

(2015) Tove Fall et al.   DIABETES

Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study

(2015) Charlotte Andersson et al.   DIABETOLOGIA

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

(2015) Joost Besseling et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

(2015) Daniel I Swerdlow et al.   LANCET

Risk of diabetes in patients treated with HMG-CoA reductase inhibitors

(2015) Yongin Cho et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Different effects of statins on induction of diabetes mellitus: an experimental study

(2015) Shui-Ping Zhao et al.   Drug Design Development and Therapy

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

(2014) Naveed A. Sattar et al.   ATHEROSCLEROSIS SUPPLEMENTS

Pleiotropic Effects of Lipid Genes on Plasma Glucose, HbA1c, and HOMA-IR Levels

(2014) N. Li et al.   DIABETES

Statin treatment and new-onset diabetes: A review of proposed mechanisms

(2014) Marilyne Brault et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Statin Use And Risk Of Developing Diabetes In Cardiovascular Disease: Systematic Literature Review And Meta-Analysis

(2014) D. Thakker et al.   VALUE IN HEALTH

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

(2014) C. R. Dormuth et al.   BMJ-British Medical Journal

Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study

(2014) Hae-Young Lee et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus

(2013) Eliano Pio Navarese et al.   AMERICAN JOURNAL OF CARDIOLOGY

Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?

(2013) Eliano Pio Navarese et al.   American Journal of Cardiovascular Drugs

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Statins for primary prevention of cardiovascular disease

(2013) C. Michael Minder et al.   CURRENT OPINION IN CARDIOLOGY

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2013)   EUROPEAN HEART JOURNAL

Risk of incident diabetes among patients treated with statins: population based study

(2013) A. A. Carter et al.   BMJ-British Medical Journal

Management of Cardiovascular Risk: The Importance of Meeting Lipid Targets

(2012) Antonio M. Gotto et al.   AMERICAN JOURNAL OF CARDIOLOGY

Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy

(2012) David D. Waters et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Balancing the cardiometabolic benefits and risks of statins

(2012) Gerald F Watts et al.   LANCET

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

(2012) Paul M Ridker et al.   LANCET

Statins: Is It Really Time to Reassess Benefits and Risks?

(2012) Allison B. Goldfine   NEW ENGLAND JOURNAL OF MEDICINE

Statins and the risk of new-onset diabetes

(2011) David Preiss et al.   CURRENT OPINION IN LIPIDOLOGY

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin

(2011) David D. Waters et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice

(2010) J. K. Kruit et al.   DIABETOLOGIA

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis

(2009) S. N. Rajpathak et al.   DIABETES CARE

Impact of Simvastatin on Adipose Tissue: Pleiotropic Effectsin Vivo

(2009) Tayeba Khan et al.   ENDOCRINOLOGY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE